JAZZ PHARMACEUTICALS FRANCE
- Country
- ๐ซ๐ทFrance
- Ownership
- -
- Established
- 2003-01-01
- Employees
- -
- Market Cap
- -
An Open-label Extension Study to Investigate Possible Drug-drug Interactions Between Clobazam and Cannabidiol
- First Posted Date
- 2015-10-01
- Last Posted Date
- 2022-09-28
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 18
- Registration Number
- NCT02564952
A Randomized Controlled Trial to Investigate Possible Drug-drug Interactions Between Clobazam and Cannabidiol
- Conditions
- Interventions
- First Posted Date
- 2015-10-01
- Last Posted Date
- 2022-09-28
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 20
- Registration Number
- NCT02565108
An Open-label Extension Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)
- First Posted Date
- 2015-09-09
- Last Posted Date
- 2022-07-14
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 199
- Registration Number
- NCT02544750
- Locations
- ๐บ๐ธ
Massachusetts General Hospital, Boston, Massachusetts, United States
A Randomized Controlled Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)
- Conditions
- Interventions
- First Posted Date
- 2015-09-09
- Last Posted Date
- 2022-09-28
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 224
- Registration Number
- NCT02544763
- Locations
- ๐บ๐ธ
Minnesota Epilepsy Group, P.A, Saint Paul, Minnesota, United States
๐ช๐ธCentro Mรฉdico Teknon, Barcelona, Spain
๐บ๐ธLe Bonheur Children's Hospital, Memphis, Tennessee, United States
EAP of CPX-351 (VYXEOS) for Patients 60-75 Years of Age With Secondary AML
- Conditions
- First Posted Date
- 2015-08-26
- Last Posted Date
- 2017-08-22
- Lead Sponsor
- Jazz Pharmaceuticals
- Registration Number
- NCT02533115
- Locations
- ๐บ๐ธ
UCLA Ronald Reagan Medical Center, Los Angeles, California, United States
๐บ๐ธNorthside Hospital, Atlanta, Georgia, United States
๐บ๐ธRush University Medical Center, Chicago, Illinois, United States
A Study of GWP42006 in People With Focal Seizures - Part A
- First Posted Date
- 2015-02-24
- Last Posted Date
- 2022-12-20
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 32
- Registration Number
- NCT02369471
A Study of GWP42006 in People With Focal Seizures - Part B
- First Posted Date
- 2015-02-19
- Last Posted Date
- 2022-12-20
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 162
- Registration Number
- NCT02365610
"Six-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in OSA"
- First Posted Date
- 2015-01-28
- Last Posted Date
- 2019-09-09
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 174
- Registration Number
- NCT02348619
- Locations
- ๐บ๐ธ
Broward Research Group, Inc., Hollywood, Florida, United States
๐บ๐ธEmory Sleep Center, Atlanta, Georgia, United States
๐บ๐ธJohns Hopkins Hospital, Baltimore, Maryland, United States
"Twelve-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in Narcolepsy"
- First Posted Date
- 2015-01-28
- Last Posted Date
- 2019-07-23
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 239
- Registration Number
- NCT02348593
- Locations
- ๐จ๐ฆ
Pediatric Sleep Research Inc., Toronto, Ontario, Canada
๐บ๐ธStanford University Center for Narcolepsy, Redwood City, California, United States
๐บ๐ธSleep Med of South Carolina, Columbia, South Carolina, United States
"A Long-Term Safety Study of JZP-110 in the Treatment of Excessive Sleepiness in Subjects With Narcolepsy or OSA"
- First Posted Date
- 2015-01-28
- Last Posted Date
- 2019-06-25
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 645
- Registration Number
- NCT02348632
- Locations
- ๐บ๐ธ
Center for Sleep and Circadian Neurobiology, Philadelphia, Pennsylvania, United States
๐บ๐ธOhio Sleep Medicine & Neuroscience Institute, Dublin, Ohio, United States
๐บ๐ธUPMC Sleep Medicine Center, Pittsburgh, Pennsylvania, United States